For many years, Myc function has been linked to the control of cell-cycle progression. Now, increasing evidence shows that Myc also controls cell growth, and that these two processes are regulated independently.
A balance of cell growth, cell proliferation, apoptosis and terminal differentiation is important in ensuring the normal development of an organism. Defects in these processes can lead to developmental abnormalities and, in some cases, cancer progression. The genes involved in regulating these various processes therefore need to be tightly controlled. The c-myc proto-oncogene, which is often rearranged and deregulated in a wide range of tumors, encodes a key regulator of cell proliferation and apoptosis. Recent studies have now demonstrated that Myc has a role in regulating cell growth and that this is independent of its effects on the cell cycle [1] [2] [3] [4] .
Early studies of Myc function in the cell cycle showed that ectopic expression of Myc in culture can be sufficient to induce quiescent cells, which are in the G0 phase of the cell cycle, to progress to the G1 phase [5] . In other systems, Myc needs to cooperate with activated forms of the Ras oncoprotein to induce cell-cycle entry [6] . On the basis of these findings, Myc has been viewed as a cellcycle regulator, analogous to cyclins or members of the E2F-family of transcription factors. Indeed, activation of conditional alleles of Myc leads to a rapid activation of the kinase activity of cyclin-dependent kinase 2 (Cdk2) in the Cdk2-cyclin E complex and of E2F-dependent transcription [7] . Myc and Ras cooperate in both of these processes [6] . In similar experiments, ectopic expression of Myc has been shown to partially antagonize the effects of the cell-cycle inhibitors p27 Kip1 and p16 Ink4a , prompting the suggestion that Myc induces cell-cycle entry by suppressing p27 Kip1 function [8] .
The first indications that the role of Myc was not that simple came from the study of a rat fibroblast cell line in which both alleles of c-myc had been ablated [9] . Such cells were viable and, as expected, showed greatly reduced rates of cell proliferation. Unexpectedly, the major defect in these cells was a deficiency in cell growth, defined by the accumulation of cell mass and a deficiency in global mRNA and protein synthesis. Indeed, although these cells showed cell-cycle defects in the G1 phase, including a significantly delayed phosphorylation of the retinoblastoma protein (Rb), the phosphorylation of Rb in control and Myc-deficient cells occurred when the cells were at the same size. This finding would argue that a delay in cell growth might be the primary cause for the delay in cell-cycle progression.
A paper by Schuhmacher et al. [1] published recently in Current Biology has extended these studies to look at the effect of Myc induction in resting B cells. This group was able to identify conditions under which activation of Myc alone was insufficient to induce cell-cycle entry but could still stimulate the cells to grow. Additionally, a number of potential target genes of Myc thought to be involved in cell growth were activated under these conditions. Finally, experiments using roscovitine, a Cdk2 inhibitor, showed that Myc's effects on growth were independent of Cdk2 activation and, therefore, of the cell cycle [1] . In similar studies in fibroblasts, using a conditional expression system, Myc had been shown to induce cell growth, but the cells also entered the cell cycle, making it impossible to dissect these two effects [2] . In addition, Iritani and Eisenman [3] have reported a Myc-dependent increase in B-cell size in mice that constitutively express Myc throughout B-cell development and these effects were observed independent of the cell-cycle phase.
Perhaps the most compelling study comes from Johnston et al. [4] , who analysed the function of the Drosophila Myc homologue, dMyc, during development. Using the wing imaginal disc as a model system for studying the effects of deregulated dMyc expression, clones with eliminated dMyc expression exhibited a retardation in cellular growth and a reduced cell size, whereas overproduction of dMyc increased both growth rate and cell size. Overexpression of dMyc promoted progression from the G1 to S phase, which was then compensated by a prolonged S-G2 phase. The overall length of the cell cycle was therefore unchanged and cell doubling times were not altered, resulting in no increase in total cell number.
These findings should be compared with previous studies from the Edgar and Lehner laboratories [10, 11] in which cell-cycle progression had been manipulated in the Drosophila wing or imaginal disc by either enhancing or lowering the level of activity of the Drosophila homologues of E2F, Rb or Cdc2 [10, 11] . In every case, the clone size was maintained, because any alteration in cell number was balanced by a compensatory alteration in cell size.
Clearly, in Drosophila, Myc has an important effect on cell growth and does not act purely as a regulator of the cell cycle.
So where do these findings leave us? Johnston et al. [4] argue from their findings that Myc acts predominantly as a regulator of cell growth, and indeed many putative target genes of Myc are involved in cell metabolism [12] . Could it be that the effects of Myc on cell-cycle progression are all indirectly mediated by its effects on cell growth? Two findings argue that this is not the case: First, in exponentially growing rat fibroblasts, conditional activation of Myc does not alter the kinetics of cell growth or cell proliferation [7] . Nevertheless, activation of Myc leads to a premature activation of Cdk2-cyclin E and of E2F-dependent transcription in cells early after exit from mitosis. At this time, cells have not reached the size usually required to pass the restriction point and activate Cdk2-cyclin E activity. This demonstrates that these cell-cycle effects are independent of any effect of Myc on cell growth. Second, at least three genes directly involved in cell-cycle progression have now been suggested to be direct target genes of Myc: these encode the cell-cycle phosphatase Cdc25a [13] , E2F2 [14] , and cyclin D2 [15] . For example, induction of cyclin D2 occurs via direct binding of Myc-Max complexes in the cyclin D2 promoter upstream of the start site of transcription, and cyclin D2 protein accumulates rapidly upon induction of Myc [15] . Importantly, Myc activates transcription of the cyclin D2 gene even in the presence of cycloheximide, thereby precluding any indirect effects mediated via cell growth, which requires protein synthesis. Judged by these criteria, a stimulation of cell growth and activation of cell proliferation by Myc appear to be mediated by distinct sets of target genes. But detailed mechanisms will only be completely resolved when Myc function is analysed in various lines of fibroblasts in which single target genes of Myc are specifically and individually eliminated. Such studies are just beginning to emerge [15, 16] .
If Myc indeed stimulates both growth and cell-cycle entry independently, however, why does it need a cooperating protein like Ras? And why, for example, does Ras synergize with Myc in Cdk activation? Clearly, models in which both oncogenes control separate physiological processes are unlikely, since Ras, like Myc, has been implicated in the control of both cell growth and cell-cycle progression via distinct effector pathways [17] . Rather, it appears that the control of cell proliferation by Myc and Ras is intimately coordinated at multiple levels. For example, in the REF52 rat fibroblast cell line ectopic expression of Myc is unable to promote G1 progression and target gene activation, because Myc protein is rapidly degraded. Expression of activated Ras stabilises Myc protein and allows activation of Myc target genes and S-phase entry, suggesting that Ras acts in a pathway controlling Myc stability [18] .
Similarly, recent work shows that Cdk2-cyclin E activity is inhibited by both p27 Kip1 and the Rb-family member p130 in quiescent cells and both inhibitors dissociate from Cdk2-cyclin E complexes upon mitogenic stimulation [19] . The processes controlling each inhibitor are very different, however, and although Myc function has been linked to p27 Kip1 [15] , no evidence suggests that Myc controls p130 function. Potentially, therefore, Myc and Ras collaborate in Cdk activation by controlling distinct inhibitor pathways. Finally, recent work indicates that Myc recruits TRRAP, a component of a histone acetylation complex, to Myc-binding sites on DNA [20] , and that at least some target genes are controlled by Myc via changes in histone acetylation. An attractive hypothesis, therefore, is that Myc not only activates target genes directly, but also alters the chromatin structure of the promoters of such genes to make them accessible for a second -for example, Ras-dependent -signal. In this way, Myc would make cells and promoters permissive for mitogenic signalling by Ras.
The findings also suggest that the ability of Myc to stimulate cell proliferation results from co-ordinate changes in expression of a potentially large number of target genes. But, irrespective of the mechanism by which Myc activates its target genes, it is now clear that, besides the role of Myc in the control of cell-cycle progression, we must also focus on the control of cell growth as an additional major function of Myc.
